Literature DB >> 18256985

The immunology of multiple sclerosis.

Amit Bar-Or1.   

Abstract

Recent years have witnessed a remarkable growth in literature related to the biology and treatment of multiple sclerosis (MS). The focus of this article is on aspects of the human immune response that have been implicated in the MS disease process and, as a corollary, represent rational targets for the development of safe and effective therapies. Much of the thinking about immune pathophysiology in patients with MS has been shaped by studies in animal models of central nervous system (CNS) inflammation. Translation to the human disease has continued to pose challenges. A simplified model of MS immune pathophysiology is presented to illustrate the basic principles by which peripheral immune activation, as well as compartmentalized immune responses within the CNS, is likely to impact the disease process and to identify the putative sites of action of current and future MS treatments.

Entities:  

Mesh:

Year:  2008        PMID: 18256985     DOI: 10.1055/s-2007-1019124

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  35 in total

Review 1.  Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.

Authors:  Matthias Mehling; Ludwig Kappos; Tobias Derfuss
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

Review 2.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

Review 3.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

Review 4.  The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.

Authors:  Yang Mao-Draayer; Jeffrey Sarazin; David Fox; Elena Schiopu
Journal:  Clin Immunol       Date:  2016-11-23       Impact factor: 3.969

Review 5.  Clinical relevance of brain volume measures in multiple sclerosis.

Authors:  Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

6.  Stopping Disease-Modifying Therapy in Nonrelapsing Multiple Sclerosis: Experience from a Clinical Practice.

Authors:  Gary Birnbaum
Journal:  Int J MS Care       Date:  2017 Jan-Feb

7.  Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls.

Authors:  Delgertsetseg Chuluundorj; Scott A Harding; David Abernethy; Anne Camille La Flamme
Journal:  Immunol Cell Biol       Date:  2016-10-03       Impact factor: 5.126

8.  Immune response in human cerebral cavernous malformations.

Authors:  Changbin Shi; Robert Shenkar; Hongyan Du; Edward Duckworth; Harish Raja; H Hunt Batjer; Issam A Awad
Journal:  Stroke       Date:  2009-03-12       Impact factor: 7.914

9.  Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

Authors:  Mark S Freedman; Johanne M Kaplan; Silva Markovic-Plese
Journal:  J Clin Cell Immunol       Date:  2013-07-08

10.  The choroid plexus response to a repeated peripheral inflammatory stimulus.

Authors:  Fernanda Marques; João C Sousa; Giovanni Coppola; Daniel H Geschwind; Nuno Sousa; Joana A Palha; Margarida Correia-Neves
Journal:  BMC Neurosci       Date:  2009-11-18       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.